Streetbeat News

Price Targets

CABA

In the last quarter, analysts have provided bullish ratings for Cabaletta Bio (NASDAQ:CABA) with 5 bullish and 1 somewhat bullish ratings. Over the past 3 months, 6 analysts have offered 12-month price targets for Cabaletta Bio, with an average price target of $27.17, a high of $39.00 and a low of $17.00. The average price target has increased by 87.38% over the past month.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 3:00 pm

BGS

Piper Sandler has downgraded B&G Foods from Neutral to Underweight and lowered its price target from $14 to $8, causing B&G Foods shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:52 pm

WLK

Citigroup analyst Patrick Cunningham has maintained a Neutral rating on Westlake (NYSE:WLK) and lowered the price target from $142 to $135.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:51 pm

INTC

Roth MKM analyst Suji Desilva has reiterated a Neutral rating on Intel (NASDAQ:INTC) and maintained a $35 price target.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:48 pm

COIN

Mizuho analyst Dan Dolev has reiterated an 'Underperform' rating on Coinbase Global (NASDAQ:COIN) and maintained a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:41 pm

HRMY

Mizuho analyst Graig Suvannavejh has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $54.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:39 pm

LNTH

Mizuho analyst Anthony Petrone has reiterated a 'Buy' rating on Lantheus Holdings (NASDAQ:LNTH) and maintained a price target of $125.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:37 pm

SPOT

Benchmark analyst Mark Zgutowicz has reiterated a 'Buy' rating on Spotify Technology (NYSE:SPOT) and maintained a price target of $205.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:35 pm

TAP

Roth MKM analyst Bill Kirk has reiterated a 'Buy' rating on Molson Coors Beverage (NYSE:TAP) and maintained a price target of $77.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:34 pm

VRTX

Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $456.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:23 pm